4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 64 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $345,734 | -46.2% | 27,159 | -23.7% | 0.00% | 0.0% |
| Q2 2023 | $643,220 | +39.6% | 35,596 | +32.8% | 0.00% | 0.0% |
| Q1 2023 | $460,830 | +73.2% | 26,808 | +123.8% | 0.00% | – |
| Q4 2022 | $266,076 | -6.6% | 11,980 | -66.2% | 0.00% | – |
| Q3 2022 | $285,000 | +13.1% | 35,469 | -1.7% | 0.00% | – |
| Q2 2022 | $252,000 | -49.1% | 36,083 | +10.2% | 0.00% | -100.0% |
| Q1 2022 | $495,000 | -36.6% | 32,746 | -8.1% | 0.00% | 0.0% |
| Q4 2021 | $781,000 | +30.2% | 35,614 | +60.0% | 0.00% | 0.0% |
| Q3 2021 | $600,000 | +84.0% | 22,265 | +64.2% | 0.00% | – |
| Q2 2021 | $326,000 | -36.0% | 13,558 | +15.5% | 0.00% | -100.0% |
| Q1 2021 | $509,000 | – | 11,737 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 831,267 | $22,419,000 | 5.52% |
| Aquilo Capital Management, LLC | 1,099,944 | $29,665,000 | 5.39% |
| BVF INC/IL | 2,005,862 | $54,098,000 | 2.11% |
| Casdin Capital, LLC | 1,115,455 | $30,084,000 | 0.75% |
| Soleus Capital Management, L.P. | 120,900 | $3,261,000 | 0.51% |
| Eagle Health Investments LP | 57,090 | $1,540,000 | 0.49% |
| Centiva Capital, LP | 358,863 | $7,220,000 | 0.45% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $106,206,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,003,447 | $27,063,000 | 0.21% |
| Perceptive Advisors | 375,256 | $10,121,000 | 0.15% |